Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to be well-tolerated
Related news for (BCEL)
- BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
- BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
- Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
- Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
- Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives